🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s DYN Holdings & Trades

First Buy
Q4 2025
Duration Held
2 Quarters
Largest Add
Q4 2025
+250,065 Shares
Current Position
323,051 Shares
$5.86 M Value

Ken Fisher's DYN Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 323,051 shares of Dyne Therapeutics, Inc. (DYN) worth $5.86 M, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in DYN, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 72,986 shares.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Dyne Therapeutics (DYN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Dyne Therapeutics (DYN) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +72,986 Add 29.19% 323,051 $18.13
Q4 2025 +250,065 New Buy 250,065 $19.56

Ken Fisher's Dyne Therapeutics Investment FAQs

Ken Fisher first purchased Dyne Therapeutics, Inc. (DYN) in Q4 2025, acquiring 250,065 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Dyne Therapeutics, Inc. (DYN) for 2 quarters since Q4 2025.

Ken Fisher's largest addition to Dyne Therapeutics, Inc. (DYN) was in Q4 2025, adding 250,065 shares worth $4.89 M.

According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 323,051 shares of Dyne Therapeutics, Inc. (DYN), valued at approximately $5.86 M.

As of the Q1 2026 filing, Dyne Therapeutics, Inc. (DYN) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Dyne Therapeutics, Inc. (DYN) was 323,051 shares, as reported at the end of Q1 2026.